Key Takeaways Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% ...

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Major U.S. stock indexes were higher at midday as markets awaited more information about potential White House tariff deals.

On an adjusted basis, Regeneron earned $8.22 per share in the first quarter, below the average analyst estimate of $8.82, ...